# BPC-157 Research: Mechanism, Tendon Healing, and Human Pilots > BPC-157 research summarized: the VEGFR2-Akt-eNOS angiogenesis mechanism, the transected-tendon healing data, the gastric-ulcer cytoprotection lineage, and the three small human pilot studies, each cited. The studies behind the console, organized by what they measured — and projected at the depth their evidence earns. ## BPC-157 mechanism of action BPC-157 research centers on one best-characterized mechanism: angiogenesis. The peptide up-regulates expression of the VEGFR2 receptor and promotes its internalization, activating the downstream VEGFR2-Akt-eNOS (nitric-oxide) pathway [3]. In chick chorioallantoic membrane, rat hindlimb-ischemia and human-endothelial-cell models, this raised vessel density and accelerated blood-flow recovery in ischemic muscle; blocking endocytosis abolished the effect — evidence the receptor traffic is mechanistically required, not incidental [3]. Around that core, the literature reports several converging routes: modulation of the nitric-oxide system (vasomotor tone, and counteraction of NO-related damage), the FAK-paxillin pathway governing fibroblast migration and outgrowth, growth-hormone-receptor up-regulation in tendon fibroblasts, Egr-1/NAB2/JAK-2 early-response signaling, and modulation of serotonergic and dopaminergic systems in CNS models [1]. A 2025 review frames the unifying account around angiogenesis plus modulation of nitric-oxide-mediated damage [8]. The primary molecular targets named across this work are VEGFR2 (KDR), endothelial nitric oxide synthase (eNOS), the growth-hormone receptor, and the FAK-paxillin complex. ## Tendon and ligament healing studies The most-cited soft-tissue result is the transected rat Achilles tendon. BPC 157 — dosed at 10 µg, 10 ng or 10 pg per rat, given once daily intraperitoneally and also tested locally — accelerated healing across biomechanical, functional, microscopic and macroscopic measures, producing better collagen organization and restored tendon integrity against untreated controls [2]. In the same work, rat tendocytes in culture showed stimulated outgrowth, and the tendon fibroblasts up-regulated the growth-hormone receptor at mRNA and protein level [2]. The striking detail is the dose span: effects were reported across roughly nine orders of magnitude, from 10 pg to 10 µg per rat [2]. That is a feature of the animal data worth stating plainly rather than smoothing over. It does not translate into a human dose, and no controlled human tendon trial exists. ## The cytoprotection lineage BPC-157 began as a gastric-cytoprotection finding. In a rat gastric-ulcer model, BPC 157 at 400 ng/kg and 800 ng/kg reduced ulcer area and accelerated healing, with intramuscular delivery outperforming intragastric and an ulcer-formation inhibition ratio of 45.7-65.6% at the higher dose; it also accelerated glandular-epithelium rebuilding and granulation-tissue formation [4]. That gastric result anchors a broader cytoprotection program spanning liver, kidney, cardiac and ocular models. The full organ-protection record — ethanol, lithium-overdose toxicity, intra-abdominal hypertension, and ocular models — is consolidated on the [BPC-157 cytoprotection research](/cytoprotection) page. The framework there is the classical cytoprotection concept of Robert and Szabo, into which BPC-157's distant-organ effects are fitted. ## Human pilot studies of BPC-157 Human evidence is limited to three small pilots, none controlled. A 2025 intravenous safety pilot infused BPC-157 (up to 20 mg) into two healthy adults; it was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers — a feasibility signal, explicitly not an efficacy trial, at n=2 [9]. A 2024 interstitial-cystitis pilot (uncontrolled, n=12) gave a single intravesical dose during cystoscopy and reported symptom resolution in most patients [11]. An intra-articular knee-pain case series rounds out the three. Separately, a historical industrial program (PL 14736 / PLD-116) reported BPC-157 was safe in early inflammatory-bowel-disease trials [1]. A 2025 narrative review, *Regeneration or Risk?*, concludes that despite broad preclinical support the human data are extremely limited, rigorous large-scale trials are lacking, and BPC-157 should be considered investigational and used with caution given regulatory controversy and non-regulated availability [10]. That conclusion is the appropriate headline for the human record. ## First pharmacokinetic characterization The first formal pharmacokinetic, distribution, metabolism and excretion study (2022, rats and beagle dogs) reported linear pharmacokinetics, a very short elimination half-life of under 30 minutes, and intramuscular bioavailability around 14-19% in rats and 45-51% in dogs, with the peptide breaking down rapidly into small fragments that enter normal amino-acid metabolism and excretion via urine and bile [5]. These figures and the routes studied are detailed on the [BPC-157 half-life and pharmacokinetics](/dosage) page. A short half-life is consistent with the repeated daily dosing used throughout the animal literature. Two qualifications belong on this record. First, a large share of the foundational literature comes from a single research group, which newer authors explicitly flag as an independent-replication question rather than a settled body of work [10]. Second, the breadth of the cited effects — tendon, gut, liver, cardiac, ocular — is real in the models but does not narrow into a single validated human indication. The 2025 narrative review reads this combination, broad preclinical signal and minimal human data, as the reason to treat BPC-157 as investigational [10]. The console keeps the two apart: a finding is logged where its study put it, and the human-translation gap is logged separately as a gap. --- The BPC-157 record projected at depth — the cited preclinical findings held on the near plane, the three human pilots a plane back, and the long-term-safety void left dim at the far edge; no clinic behind the projection and nothing here prescribed or sold.